Morphic Holding is focused on inflammatory ... contrary to injectable Zepbound. The article "Is Eli Lilly a Buy? Analyst Confidence Grows for 2025" first appeared on MarketBeat.
In the third quarter, Eli Lilly completed the acquisition of Morphic Therapeutic ... 20 have a “Strong Buy” rating, one has a “Moderate Buy,” and four rate it a “Hold.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback